JP2010506950A5 - - Google Patents

Download PDF

Info

Publication number
JP2010506950A5
JP2010506950A5 JP2009533499A JP2009533499A JP2010506950A5 JP 2010506950 A5 JP2010506950 A5 JP 2010506950A5 JP 2009533499 A JP2009533499 A JP 2009533499A JP 2009533499 A JP2009533499 A JP 2009533499A JP 2010506950 A5 JP2010506950 A5 JP 2010506950A5
Authority
JP
Japan
Prior art keywords
hydrogen
lower alkyl
independently
formula
alkoxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2009533499A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010506950A (ja
JP5298022B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2007/081607 external-priority patent/WO2008048991A2/en
Publication of JP2010506950A publication Critical patent/JP2010506950A/ja
Publication of JP2010506950A5 publication Critical patent/JP2010506950A5/ja
Application granted granted Critical
Publication of JP5298022B2 publication Critical patent/JP5298022B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2009533499A 2006-10-18 2007-10-17 有機化合物 Expired - Fee Related JP5298022B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US82998006P 2006-10-18 2006-10-18
US60/829,980 2006-10-18
US95234107P 2007-07-27 2007-07-27
US60/952,341 2007-07-27
PCT/US2007/081607 WO2008048991A2 (en) 2006-10-18 2007-10-17 Organic compounds

Publications (3)

Publication Number Publication Date
JP2010506950A JP2010506950A (ja) 2010-03-04
JP2010506950A5 true JP2010506950A5 (https=) 2010-11-25
JP5298022B2 JP5298022B2 (ja) 2013-09-25

Family

ID=39276877

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2009533499A Expired - Fee Related JP5298022B2 (ja) 2006-10-18 2007-10-17 有機化合物

Country Status (15)

Country Link
US (1) US8222248B2 (https=)
EP (1) EP2074089B1 (https=)
JP (1) JP5298022B2 (https=)
KR (1) KR20090071642A (https=)
AR (1) AR063311A1 (https=)
AU (1) AU2007311087B2 (https=)
BR (1) BRPI0718478A2 (https=)
CA (1) CA2666880A1 (https=)
CL (1) CL2007002974A1 (https=)
ES (1) ES2440253T3 (https=)
MX (1) MX2009004047A (https=)
PE (1) PE20080888A1 (https=)
RU (1) RU2009118489A (https=)
TW (1) TW200829563A (https=)
WO (1) WO2008048991A2 (https=)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0519058A2 (pt) 2004-12-14 2008-12-23 Astrazeneca Ab composto ou um sal prà-droga farmaceuticamente aceitÁvel do mesmo, mÉtodos para produzir uma inibiÇço da atividade de dgat1 e para tratar diabete melito e/ou obesidade em um animal de sangue quente, uso de um composto, composiÇço farmacÊutica, e, processo para preparar um composto
WO2007071966A1 (en) 2005-12-22 2007-06-28 Astrazeneca Ab Pyrimido- [4, 5-b] -oxazines for use as dgat inhibitors
CN101460470B (zh) 2006-05-30 2011-05-18 阿斯利康(瑞典)有限公司 作为dgat1抑制剂的1,3,4-二唑衍生物
MX2008015228A (es) 2006-05-30 2008-12-12 Astrazeneca Ab Acido 5-fenilamino-1,3,4-oxadiazol-2-ilcarbonilamino-4-fenoxi-cicl ohexanocarboxilico sustituido como inhibidor de diacilglicerol aciltransferasa de acetil coenzima a.
NZ586104A (en) 2007-12-20 2012-02-24 Astrazeneca Ab Carbamoyl compounds as dgat1 inhibitors 190
WO2009112445A1 (en) * 2008-03-10 2009-09-17 Novartis Ag Method of increasing cellular phosphatidyl choline by dgat1 inhibition
WO2010039668A2 (en) * 2008-10-01 2010-04-08 The Regents Of The University Of California Inhibitors of cyclin kinase inhibitor p21
GB0821913D0 (en) 2008-12-02 2009-01-07 Price & Co Antibacterial compounds
WO2010107768A1 (en) * 2009-03-18 2010-09-23 Schering Corporation Bicyclic compounds as inhibitors of diacylglycerol acyltransferase
TW201103895A (en) 2009-06-19 2011-02-01 Astrazeneca Ab Chemical compounds
EP2456310A4 (en) * 2009-07-23 2013-01-23 Univ Vanderbilt SUBSTITUTED BENZOIMIDAZOLSULFONAMIDES AND SUBSTITUTED INDOLSULFONAMIDES AS MGLUR4 POTENTIATORS
KR101194995B1 (ko) * 2009-10-14 2012-10-29 주식회사 이큐스앤자루 신규한 2-페닐-벤즈이미다졸 또는 2-페닐-벤즈옥사졸 유도체 또는 이의 약학적으로 허용가능한 염, 이의 제조방법 및 이를 유효성분으로 함유하는 항바이러스용 약학적 조성물
WO2011099832A2 (en) * 2010-02-12 2011-08-18 Crystalgenomics, Inc. Novel benzimidazole compound, preparation method thereof and pharmaceutical composition comprising the same
ES2803556T3 (es) 2010-06-01 2021-01-27 Summit Oxford Ltd Compuestos para el tratamiento de enfermedades asociadas a clostridium difficile
CN104159587A (zh) * 2012-01-06 2014-11-19 南佛罗里达大学 组合物、使用方法、以及治疗方法
MX365640B (es) 2012-12-21 2019-06-10 Plexxikon Inc Compuestos y metodos para la modulacion de quinasas y sus indicaciones.
WO2014151630A2 (en) 2013-03-15 2014-09-25 Irm Llc Compounds and compositions for the treatment of parasitic diseases
US9296754B2 (en) 2013-03-15 2016-03-29 Novartis Ag Compounds and compositions for the treatment of parasitic diseases
WO2014151729A1 (en) 2013-03-15 2014-09-25 Irm Llc Compounds and compositions for the treatment of parasitic diseases
BR112016014004B1 (pt) 2013-12-19 2022-11-01 Novartis Ag Compostos para tratamento de doenças parasíticas, seus usos, e composições farmacêuticas
AU2015210833B2 (en) 2014-02-03 2019-01-03 Vitae Pharmaceuticals, Llc Dihydropyrrolopyridine inhibitors of ROR-gamma
WO2015166398A1 (en) * 2014-04-30 2015-11-05 Aurigene Discovery Technologies Limited 3h-imidazo[4,5-b]pyridine derivatives as dihydroorotate dehydrogenase inhibitors
JP6564029B2 (ja) 2014-10-14 2019-08-21 ヴァイティー ファーマシューティカルズ,エルエルシー Ror−ガンマのジヒドロピロロピリジン阻害剤
US9845308B2 (en) 2014-11-05 2017-12-19 Vitae Pharmaceuticals, Inc. Isoindoline inhibitors of ROR-gamma
US9663515B2 (en) 2014-11-05 2017-05-30 Vitae Pharmaceuticals, Inc. Dihydropyrrolopyridine inhibitors of ROR-gamma
US10905665B2 (en) 2015-06-24 2021-02-02 Duke University Chemical modulators of signaling pathways and therapeutic use
DK3331876T3 (da) 2015-08-05 2021-01-11 Vitae Pharmaceuticals Llc Modulators of ror-gamma
MA53943A (fr) 2015-11-20 2021-08-25 Vitae Pharmaceuticals Llc Modulateurs de ror-gamma
TWI757266B (zh) 2016-01-29 2022-03-11 美商維它藥物有限責任公司 ROR-γ調節劑
US9481674B1 (en) 2016-06-10 2016-11-01 Vitae Pharmaceuticals, Inc. Dihydropyrrolopyridine inhibitors of ROR-gamma
ES2973850T3 (es) * 2016-09-20 2024-06-24 Centre Leon Berard Derivados del benzoimidazol como agentes anticancerígenos
CN115650976A (zh) 2017-07-24 2023-01-31 生命医药有限责任公司 RORγ的抑制剂
WO2019018975A1 (en) 2017-07-24 2019-01-31 Vitae Pharmaceuticals, Inc. INHIBITORS OF ROR GAMMA
US10513515B2 (en) 2017-08-25 2019-12-24 Biotheryx, Inc. Ether compounds and uses thereof
CA3106239A1 (en) 2018-07-27 2020-01-30 Biotheryx, Inc. Bifunctional compounds as cdk modulators
NZ773110A (en) * 2018-09-18 2024-11-29 Terns Inc Compounds for treating certain leukemias
WO2020120576A1 (en) * 2018-12-11 2020-06-18 Fundació Institut De Recerca Biomèdica (Irb Barcelona) p38α AUTOPHOSPHORYLATION INHIBITORS
AU2020311940A1 (en) 2019-07-11 2022-02-03 ESCAPE Bio, Inc. Indazoles and azaindazoles as LRRK2 inhibitors
EP4097092A1 (en) * 2020-01-28 2022-12-07 Protego Biopharma, Inc. Compounds, compositions and methods for stabilizing transthyretin and inhibiting transthyretin misfolding
WO2021222150A2 (en) 2020-04-28 2021-11-04 Anwita Biosciences, Inc. Interleukin-2 polypeptides and fusion proteins thereof, and their pharmaceutical compositions and therapeutic applications
WO2021222442A1 (en) 2020-04-29 2021-11-04 Plexxikon Inc. Synthesis of heterocyclic compounds
EP4259607A1 (en) * 2020-12-11 2023-10-18 Tmem16A Limited Benzimidazole derivatives for treating respiratory disease
US20240300939A1 (en) 2021-06-14 2024-09-12 Scorpion Therapeutics, Inc. Urea derivatives which can be used to treat cancer
CA3226162A1 (en) 2021-07-09 2023-01-12 Plexium, Inc. Aryl compounds and pharmaceutical compositions that modulate ikzf2
CN118510778A (zh) * 2022-01-12 2024-08-16 百济神州有限公司 作为DNA聚合酶θ抑制剂的噻唑并吡啶基酰胺衍生物
EP4265247A1 (en) * 2022-04-22 2023-10-25 Université Paris Cité Compounds inducing production of proteins by immune cells
CN116253755A (zh) * 2023-02-28 2023-06-13 湖南大学 一种二芳基硼酸酯类化合物的合成方法
CN117327020A (zh) * 2023-10-07 2024-01-02 中国科学院过程工程研究所 一种含苯并氮杂环结构的氨基芳香化合物及其制备方法和应用
US11970468B1 (en) 2023-10-23 2024-04-30 King Faisal University 2-(benzo[d]oxazol-2-yl)-N′-(3,5-dichlorobenzoyloxy)acetimidamide as an antimicrobial compound
CN120118037B (zh) * 2023-12-07 2025-11-28 南华大学 一类含苯甲酸酯结构的苯并咪唑类化合物、制造方法及其用途

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3551443A (en) * 1968-10-30 1970-12-29 Ciba Ltd 2-phenylbenzoxazole derivatives
JPH0678308B2 (ja) * 1985-04-24 1994-10-05 三共株式会社 フタルイミド誘導体およびそれを含有する農園芸用殺菌剤
WO1997024334A1 (en) * 1995-12-28 1997-07-10 Fujisawa Pharmaceutical Co., Ltd. Benzimidazole derivatives
EP0963371B1 (en) 1997-02-25 2003-05-02 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Substituted benzimidazoles as non-nucleoside inhibitors of reverse transcriptase
US6251689B1 (en) 1998-05-14 2001-06-26 Telik, Inc. Methods for the solid phase synthesis of combinatorial libraries of benzimidazoles benzoxazoles benzothiazoles and derivatives thereof
JP2000095767A (ja) * 1998-09-28 2000-04-04 Takeda Chem Ind Ltd 性腺刺激ホルモン放出ホルモン拮抗剤
DK1194425T3 (da) * 1999-06-23 2005-11-21 Aventis Pharma Gmbh Substituerede benzimidazoler
DE60034578D1 (de) 1999-08-26 2007-06-06 Us Health Substituierte benzimidazole als nicht-nucleosid-inhibitoren von reverser transcriptase
WO2002030894A2 (en) * 2000-09-19 2002-04-18 Taiho Pharmaceutical Co., Ltd. Compositions and methods of the use thereof achiral analogues of cc-1065 and the duocarmycins
WO2002046168A1 (en) 2000-12-07 2002-06-13 Astrazeneca Ab Therapeutic benzimidazole compounds
FR2821721B1 (fr) * 2001-03-08 2004-07-09 Laurent Locatelli Composition pour alimentation animale, utilisation de cette composition, et produit pour alimentation animale comprenant cette composition
CZ20032691A3 (en) * 2001-03-12 2004-04-14 Avanir Pharmaceuticals Benzimidazole compounds for modulating ige and inhibiting cellular proliferation
ATE369854T1 (de) * 2001-10-19 2007-09-15 Ortho Mcneil Pharm Inc 2-phenyl benzimidazole und imidazo-[4,5]-pyridine als cds1/chk2-inhibitoren und adjuvantien in der chemotherapie oder strahlungstherapie zur behandlung von krebs
TW200303742A (en) 2001-11-21 2003-09-16 Novartis Ag Organic compounds
WO2003053363A2 (en) 2001-12-19 2003-07-03 Millennium Pharmaceuticals, Inc. Human diacylglycerol acyltransferase 2 (dgat2) family members and uses therefor
TW200304820A (en) * 2002-03-25 2003-10-16 Avanir Pharmaceuticals Use of benzimidazole analogs in the treatment of cell proliferation
WO2003106439A1 (ja) * 2002-06-12 2003-12-24 株式会社ビーエフ研究所 アミロイド蓄積性疾患の画像診断プローブ化合物、老人斑/びまん性老人斑染色用化合物、ならびにアミロイド蓄積性疾患の治療薬
CA2501719C (en) * 2002-08-06 2013-02-05 Toray Industries, Inc. Remedy or preventive for kidney disease and method of diagnosing kidney disease
AU2003296405A1 (en) 2003-01-06 2004-08-10 Eli Lilly And Company Fused heterocyclic derivatives as ppar modulators
DE10306250A1 (de) * 2003-02-14 2004-09-09 Aventis Pharma Deutschland Gmbh Substituierte N-Arylheterozyklen, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
EP1620413A2 (en) 2003-04-30 2006-02-01 Cytokinetics, Inc. Compounds, compositions, and methods
CA2525764C (en) 2003-05-20 2012-07-17 Novartis Ag N-acyl nitrogen heterocycles as ligands of peroxisome proliferator-activated receptors
JPWO2005108370A1 (ja) * 2004-04-16 2008-03-21 味の素株式会社 ベンゼン化合物
WO2006044775A2 (en) 2004-10-15 2006-04-27 Bayer Pharmaceuticals Corporation Preparation and use of biphenyl-4-yl-carbonylamino acid derivatives for the treatment of obesity
US20060223849A1 (en) * 2005-03-14 2006-10-05 Mjalli Adnan M Benzazole derivatives, compositions, and methods of use as beta-secretase inhibitors
GT200600429A (es) 2005-09-30 2007-04-30 Compuestos organicos
JP2009001495A (ja) * 2005-10-13 2009-01-08 Taisho Pharmaceutical Co Ltd 2−アリール−ベンゾイミダゾール−5−カルボキサミド誘導体
CA2669736C (en) 2005-11-03 2017-02-21 Chembridge Research Laboratories, Inc. Heterocyclic compounds as tyrosine kinase modulators
CA2641880C (en) * 2006-02-10 2014-09-09 Summit Corporation Plc Treatment of duchenne muscular dystrophy

Similar Documents

Publication Publication Date Title
JP2010506950A5 (https=)
JP2011515483A5 (https=)
JP2005519083A5 (https=)
JP2012508252A5 (https=)
ECSP055774A (es) Nuevo medicamento para el tratamiento de la enfermedad pulmonar obstructiva crónica
JP2011504903A5 (https=)
ECSP088593A (es) 5-(arilsulfonil)-pirazolopiperidinas
JP2011527686A5 (https=)
JP2009519243A5 (https=)
CY1117459T1 (el) Παραγωγα που εχουν δραση αγωνιστη του βητα-2 αδρενεργικου υποδοχεα και ανταγωνιστη του μουσκαρινικου υποδοχεα
JP2011515482A5 (https=)
JP2011219498A5 (https=)
JP2013505946A5 (https=)
JP2006523194A5 (https=)
NO20033145D0 (no) Purinderivater som purinergiske reseptorantagonister
MX2009009121A (es) Aminoamidas como antagonistas de orexina.
MY169274A (en) Fused, tricyclic sulfonamide inhibitors of gamma secretase
ATE356797T1 (de) Azidfreies verfahren zur herstellung von 1,2- diaminoverbindungen
RU2009118254A (ru) Фенилацетамиды в качестве ингибиторов протеинкиназ
MX2009009384A (es) Malonamidas como antagonistas de orexina.
JPWO2023195529A5 (https=)
JP2007532627A5 (https=)
JP2017519796A5 (https=)
RU2007130144A (ru) Гетероциклические соединения в качестве антагонистов cccr2b
JP2001525394A5 (https=)